Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · IEX Real-Time Price · USD
17.65
+0.03 (0.17%)
Mar 27, 2023, 4:00 PM EDT - Market closed
Income Statement (Annual)
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Year | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|
| Revenue | 112 | 383 | 78 | 15 | 8.35 | 1.41 | 0 |
| Revenue Growth (YoY) | -70.76% | 391.03% | 420.00% | 79.58% | 491.15% | - | - |
| Gross Profit | 112 | 383 | 78 | 15 | 8.35 | 1.41 | 0 |
| Selling, General & Admin | 104 | 72 | 43 | 25.23 | 13.57 | 7.64 | 3.94 |
| Research & Development | 288 | 257 | 159 | 78.48 | 49.65 | 47.22 | 14.25 |
| Operating Expenses | 392 | 329 | 202 | 103.71 | 63.21 | 54.85 | 18.18 |
| Operating Income | -280 | 54 | -124 | -88.71 | -54.86 | -53.44 | -18.18 |
| Interest Expense / Income | 0 | 0 | 0 | 0 | 0 | -0.78 | -0.21 |
| Other Expense / Income | -14 | -1 | -1 | -4 | -5.27 | 0.42 | - |
| Pretax Income | -266 | 55 | -123 | -84.71 | -49.59 | -53.08 | -17.97 |
| Income Tax | 1 | 2 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -267 | 53 | -123 | -84.71 | -49.59 | -53.08 | -17.97 |
| Shares Outstanding (Basic) | 72 | 69 | 55 | 44 | 35 | 2 | 1 |
| Shares Outstanding (Diluted) | 72 | 74 | 55 | 44 | 35 | 2 | 1 |
| Shares Change | -2.70% | 35.04% | 25.04% | 26.60% | 1793.51% | 111.61% | - |
| EPS (Basic) | -3.71 | 0.76 | -2.24 | -1.93 | -1.43 | -29.03 | -20.80 |
| EPS (Diluted) | -3.71 | 0.71 | -2.24 | -1.93 | -1.43 | -29.03 | -20.80 |
| Free Cash Flow Per Share | 6.00 | -4.07 | 1.97 | -1.72 | -1.35 | -16.72 | -19.73 |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | - |
| Operating Margin | -250.00% | 14.10% | -158.97% | -591.39% | -656.76% | -3782.09% | - |
| Profit Margin | -238.39% | 13.84% | -157.69% | -564.73% | -593.73% | -3756.69% | - |
| Free Cash Flow Margin | 385.71% | -73.63% | 138.46% | -502.58% | -559.55% | -2163.69% | - |
| Effective Tax Rate | - | 3.64% | - | - | - | - | - |
| EBITDA | -252 | 62 | -119 | -81.13 | -45.93 | -51.25 | -16.87 |
| EBITDA Margin | -225.00% | 16.19% | -152.56% | -540.88% | -549.86% | -3626.68% | - |
| Depreciation & Amortization | 14 | 7 | 4 | 3.58 | 3.66 | 2.61 | 1.31 |
| EBIT | -266 | 55 | -123 | -84.71 | -49.59 | -53.86 | -18.18 |
| EBIT Margin | -237.50% | 14.36% | -157.69% | -564.73% | -593.73% | -3811.54% | - |
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).